In this regard, previous studies in AD patients indicate that significantly greater WMH burden in APOE4 non-carriers than APOE4 carriers, although not the case in our cohort, may constitute a possible underlying factor leading to greater GMV loss in APOE4 non-carriers [45]. This evidence concerns the gene APOE and Alzheimer disease.